Treatment of movement disorders by administration of mirtazapine

• US 6,281,207 B1
• Filed: 09/15/1999
• Issued: 08/28/2001
• Est. Priority Date: 09/15/1999
• Status: Expired due to Fees

• Current Assignee: Reed Ricter, Steven J. Hultquist
• Original Assignee: Reed Richter, Steven J. Hultquist, Thomas Giduz, Virginia Pact Richter
• Inventors: Giduz, Thomas, Richter, Virginia Pact
• Primary Examiner(s): Jarvis, William R. A.
• Application Number:
  US09/396,335
• Time in Patent Office: 713 Days
• Field of Search: 514/214.02, 514/220, 514/259, 514/288, 514/324, 514/325, 514/396, 514/397
• US Class Current: 514/214.02
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs

Abstract

A method of combating movement disorder in a patient experiencing or susceptible to same, by administerinig to the patient an effective amount of mirtazapine.

Claims

1. A method of combating movement disorder in a patient experiencing or susceptible to same, by administering to the patient an effective amount of mirtazapine.

2. The method of claim 1, wherein said movement disorder comprises dyskinesia.

3. The method of claim 1, wherein said movement disorder comprises a condition selected from the group consisting of tremors, akathisias, asterixis, atlietosis, choreaathetosis, tics, chorea/choreaform movements, dystonias, spasticity, restless legs syndrome, hyperkinetic movement disorders, hemiballismus, myoclolnus, and tardive dyskinesia.

4. The method of claim 1, wherein said movement disorder comprises tremor.

5. The method of claim 1, wherein said movement disorder comprises a peripheral neuropathy-associated tremor.

6. The method of claim 1, wherein said movement disorder comprises at least one tremor condition selected from the group consisting of Parkinsonian tremors, rubral tremors, post-traumatic tremors, drug-induced tremors, cerebellar tremors, and Tourette syndromal tremors.

7. The method of claim 1, wherein said movement disorder derives from neurological impairment of the basal ganglia.

8. The method of claim 1, wherein said movement disorder comprises a disorder selected from the group consisting of Parkinsonian tremor, action tremor and levodopa-induced dyskinesias.

9. The method of claim 1, wherein mirtazapine is administered orally to the patient.

10. The method of claim 9, wherein mirtazapine is administered orally in a dose of from about 10 to about 100 milligrams per day.

11. The method of claim 9, wherein mirtazapine is administered orally in a dose of from about 15 to about 60 milligrams per day.

12. The method of claim 1, wherein the composition does not mediate sedation in dosages effective for combating movement disorder.

13. The method of claim 1, wherein said movement disorder comprises Parkinsonian Tremor.

14. A method of combating levodopa-induced dyskiniesia in a patient receiving levodopa, comprising administerinig to the patient a composition comprising levodopa, and a levodopa-induced dyskinesia-combating amount of mirtazapine.

15. A composition for treatment of Parkinson'"'"'s Disease, comprising an effective amount of levodopa and a levodopa-induced dyskinesia-combating amount of mirtazapine.